Laropiprant/Simvastatin/Nicotinic Acid

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameLaropiprant/Simvastatin/Nicotinic Acid
Drug Alias Name辛伐他汀/烟酸/拉罗匹仑Laropiprant/Nicotinic Acid/Simvastatin拉罗匹仑/辛伐他汀/烟酸Simvastatin/Niacin/LaropiprantLaropiprant/Simvastatin/Niacin +[7] 
ClassificationSmall molecules
Mechanisms of ActionHMG-CoA reductase inhibitorsProstaglandin D2 receptor antagonistsHydroxycarboxylic acid receptor 2 agonists +[4] 
TargetsProstaglandin D2 receptorHMG-CoA reductaseHydroxycarboxylic acid receptor 2 +[4] 
Therapy Area/IndicationsHypercholesterolemiaDyslipidemiasHyperlipidemia, Familial Combined
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes LaropiprantSimvastatinNicotinic Acid
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Sharp & Dohme LLC
Active IndicationsN/A
Inactive IndicationsHypercholesterolemiaDyslipidemiasHyperlipidemia, Familial Combined

Other Information

ATC CodeN/A
Related LinksN/A